Neuromyelitis optica spectrum disorder primary prevention
|
Neuromyelitis optica spectrum disorder Microchapters |
|
Differentiating Neuromyelitis optica spectrum disorder from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Neuromyelitis optica spectrum disorder primary prevention On the Web |
|
American Roentgen Ray Society Images of Neuromyelitis optica spectrum disorder primary prevention |
|
FDA on Neuromyelitis optica spectrum disorder primary prevention |
|
CDC on Neuromyelitis optica spectrum disorder primary prevention |
|
Neuromyelitis optica spectrum disorder primary prevention in the news |
|
Blogs on Neuromyelitis optica spectrum disorder primary prevention |
|
Directions to Hospitals Treating Neuromyelitis optica spectrum disorder |
|
Risk calculators and risk factors for Neuromyelitis optica spectrum disorder primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Julinka Auta Fernandes
Overview
Primary prevention of neuromyelitis optica spectrum disorder (NMOSD) refers to preventing the initial development of the disease before its first clinical presentation. There is currently no established method for preventing NMOSD onset.[1]
Primary Prevention
There are no established measures for the primary prevention of neuromyelitis optica spectrum disorder.[1]
- Vaccination: No disease-specific vaccine is established for preventing NMOSD onset.[1]
- Preventive medication: No medication regimen is established for preventing NMOSD in individuals who have not developed the disease.[1]
- Risk-factor modification: The Neuromyelitis Optica Study Group (NEMOS) recommendations describe vitamin D deficiency and smoking as less well-established potential risk factors. These associations do not establish that vitamin D supplementation or smoking cessation prevents a first NMOSD attack.[2]
References
- ↑ 1.0 1.1 1.2 1.3 "Neuromyelitis optica spectrum disorder". MedlinePlus Medical Encyclopedia. U.S. National Library of Medicine. Retrieved 2026-10-30.
- ↑ Jarius S, Aktas O, Ayzenberg I, et al. (2023). "Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis". Journal of Neurology. 270: 3341–3368. doi:10.1007/s00415-023-11634-0. PMC 10267280 Check
|pmc=value (help). PMID 37022481 Check|pmid=value (help).